ECM
ANRO icon

ExodusPoint Capital Management’s Alto Neuroscience ANRO Stock Holding History

ExodusPoint Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,786
Closed -$334K – 2178
2025
Q4 		$334K Buy
+18,786
New +$237K ﹤0.01% 1278
2024
Q4 		– Sell
-1,162,376
Closed -$13.3M – 2147
2024
Q3 		$13.3M Buy
1,162,376
+326,283
+39% +$3.99M 0.08% 188
2024
Q2 		$8.94M Buy
836,093
+229,363
+38% +$2.98M 0.06% 277
2024
Q1 		$9.31M Buy
+606,730
New +$9.5M 0.07% 220

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ExodusPoint Capital Management's ANRO Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Alto Neuroscience (ANRO) in Q1 2026, closing a stake of 18,786 shares — an estimated $334K sold.

ExodusPoint Capital Management first reported a position in ANRO in Q1 2024 and held it in 4 quarters. The position peaked at $13.3M in Q3 2024. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Alto Neuroscience position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 18,786 Alto Neuroscience shares in Q1 2026, an estimated $334K.
  • ExodusPoint Capital Management first reported a position in Alto Neuroscience in Q1 2024 and held it in 4 quarters.
  • ExodusPoint Capital Management's Alto Neuroscience position peaked at $13.3M in Q3 2024.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.